Prognostic and predictive biomarkers in colorectal cancer: from established molecular markers to Mediator complex-related transcriptional reprogramming—a narrative review
Sep 2026· Journal of Gastrointestinal Oncology· Vol 17, pp. 319-319· 0 citations· 38 references
Medicine
TL;DR
This review evaluates Mediator complex-related transcriptional programs as a candidate regulatory layer that may complement existing CRC biomarker frameworks and concludes that CRC biomarker development should integrate rather than replace complementary information layers.
Abstract
Background and Objective Colorectal cancer (CRC) prognosis and treatment selection are increasingly informed by established molecular biomarkers, circulating tumor DNA (ctDNA), immune contexture, and multidimensional prediction models. However, these approaches mainly define tumor identity, treatment eligibility, residual disease burden, or observable tumor states and may incompletely explain how adaptive transcriptional states arise under oncogenic, stromal, immune, metastatic, or therapeutic pressure. This review evaluates Mediator complex-related transcriptional programs as a candidate regulatory layer that may complement existing CRC biomarker frameworks. Methods English-language literature was reviewed using PubMed/MEDLINE, Web of Science, and Scopus, with Google Scholar used for citation tracking. The initial search was performed on June 7, 2026, and a focused supplementary update was performed on August 17, 2026. Recent CRC biomarker studies, Mediator-related transcriptional regulation, functional heterogeneity, therapy adaptation, and germline variation in Mediator-related genes were emphasized, while earlier landmark mechanistic studies and guidelines were retained when necessary. Key Content and Findings Established clinicopathological and molecular biomarkers primarily define baseline risk, molecular identity, and treatment eligibility. Dynamic and multidimensional approaches add residual-disease, immune, stromal, spatial, and transcriptomic state information. Mediator-related programs may provide a mechanistic interpretation layer by linking transcription-factor and enhancer inputs, chromatin context, and RNA polymerase II-dependent output. Cyclin-dependent kinase 8 (CDK8)-Wnt/β-catenin represents a mechanistically strong CRC axis; Mediator subunit 12 (MED12)-linked transforming growth factor-β (TGF-β)/epithelial-mesenchymal transition (EMT) programs are strongly context dependent; emerging cyclin-dependent kinase 19 (CDK19) evidence links metabolic remodeling with immune-evasive states; and Mediator subunits 19 and 28 remain lower-maturity candidates. Current evidence does not establish germline MED12/CDK8 variants as CRC prognostic or predictive biomarkers. Conclusions CRC biomarker development should integrate rather than replace complementary information layers. Mediator-related programs are not mature stand-alone clinical biomarkers but may help interpret adaptive tumor states. Prospective clinically annotated cohorts, functional perturbation, single-cell and spatial profiling, and demonstration of incremental value beyond established biomarkers are required before clinical implementation.
Colorectal cancer (CRC) remains one of the most common malignancies worldwide and a leading cause of cancer-related mortality. Recent advances in CRC molecular biology have focused on biomarkers for early detection, prognostic stratification, treatment selection, and disease monitoring. Clinically validated biomarkers,...
Katarzyna Herbetko, Aleksandra Herbetko, Sara Suwała et al.· Cells· 0 citations
Investigation of MS-related prognostic genes and their potential biological relevance in CRC progression finds potential clues for future studies of CRC prognosis and MS-related tumor biology.
This review synthesizes current advances in CRC epidemiology, risk factors, signaling biology, clinical presentation, screening, diagnosis, and management across the care continuum, and frames CRC as a systems‐level disease in which genomic instability, epigenetic dysregulation, metabolic remodeling, tumor microenviron...
Kai-Rui Wan, Ke Tang, Ling-Long Wang et al.· MedComm· 0 citations
Background: Epithelial-derived carcinomas exhibit genomic instability due to genetic mutation and epigenetic dysregulation. Mechanisms such as DNA methylation, histone modifications, and noncoding RNA regulation may lead to tumor progression, immune evasion, and treatment resistance. Presently, gene-based and epigeneti...
Joshua George Thomas, Mohammed Ayyub, L. Annamma et al.· Biomedicines· 0 citations
Background Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy with a dismal prognosis, yet effective prognostic biomarkers and therapeutic targets remain scarce. Both epithelial-mesenchymal transition (EMT) and mitophagy are known to drive tumor progression and therapy resistance, but their synergi...
Ye-Cheng Wang, Dong-bin Liu, Kuo Liang et al.· Translational Cancer Researc...· 0 citations
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Immune checkpoint inhibitor (ICI)-based combinations have become the standard first-line systemic therapy, yet objective response rates remain modest (20-36%), and no HCC-specific immune biomarker has been validated to guide selection among...
Fady Sidhom, Emin Karabiber, R. Elbeblawy et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.